"Consistent with the National intellectual property rights (IPR) Policy, when it comes to IP, India clearly has a toe in the water, but appears ambivalent about jumping in," Patrick Kilbride, executive director of international intellectual property, US Chamber of Commerce, said yesterday.
"You cannot have it both ways. You cannot say you want to be a center of innovative growth and at the same time celebrate proposals that would undermineand drive awayinnovators," he said.
"This incremental yet important progress came hand in hand with statements associating India with an independent panel report from the UN that moves in the opposite direction. No country can have it both ways," Kilbride said.
After the India-US Trade Policy Forum meeting last week, Commerce and Industry Minister Nirmala Sitharamancited a UN report to "vindicate" India's stand on not going beyond the commitments made in the global TRIPS Agreement.
She said India was very clear that it is not ready to engage with anyone on 'TRIPS plus' issues which could lead to "ever-greening of patents or blocking of compulsory licenses".
He said it was designed to drive a narrow and extreme agenda.
The Panel's predetermined conclusions ignored decades of data and the input of nations in asserting that intellectual property is the problem with access to medicines, he alleged.
"In doing so, the Panel ignored the real culprits that stand between patients and care: excessive tariffs and taxes on imported medicines, and weak healthcare infrastructures that hinder the effective distribution of medicines. The UN's own data shows that intellectual property does not restrict access to medicines: 95 per cent of essential medicines are no longer under patent," Elliot said.
Decades of research have shown that the private sector is responsible for as much as 97 per cent of drug development. If adopted, these recommendations could prohibit the creation of future breakthrough treatments," he said.
The UN Panel among other things called on governments to drastically restrict patentability of medical innovations, make liberal use of compulsory licenses to override patents, minimise the private sector role in the research and development of new cures and put the UN itself above national governments in oversight of intellectual property rights.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
